These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 18836691)

  • 61. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
    Segreti J; Jones RN; Bertino JS
    J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.
    Barry AL; Fuchs PC; Brown SD
    Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):305-9. PubMed ID: 10385024
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin.
    O'Brien TP; Arshinoff SA; Mah FS
    J Cataract Refract Surg; 2007 Oct; 33(10):1790-800. PubMed ID: 17889778
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [In vitro fluoroquinolone resistance in ocular bacterial isolates].
    Sun XG; Wang ZQ; Li R; Chen L; Jin XY; Luo SY
    Zhonghua Yan Ke Za Zhi; 2003 Mar; 39(3):163-6. PubMed ID: 12880574
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.
    Benitez-Del-Castillo J; Verboven Y; Stroman D; Kodjikian L
    Clin Drug Investig; 2011; 31(8):543-557. PubMed ID: 21604820
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections.
    Kim SJ; Toma HS
    Ophthalmology; 2011 Jul; 118(7):1358-63. PubMed ID: 21420176
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy of moxifloxacin or gatifloxacin as prophylaxis against experimental murine Brucella melitensis infection.
    Atkins HS; Spencer S; Brew SD; Laws TR; Thirlwall RE; MacMillan AP; Brooks TJ; Simpson AJ
    Int J Antimicrob Agents; 2009 Nov; 34(5):471-3. PubMed ID: 19682862
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium.
    Sano C; Tatano Y; Shimizu T; Yamabe S; Sato K; Tomioka H
    Int J Antimicrob Agents; 2011 Apr; 37(4):296-301. PubMed ID: 21353489
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing.
    Levine JM; Noecker RJ; Lane LC; Herrygers L; Nix D; Snyder RW
    J Cataract Refract Surg; 2004 Oct; 30(10):2177-82. PubMed ID: 15474833
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy of fluoroquinolones against pathogenic oral bacteria.
    Núñez Otero V; Limeres Posse J; Carmona IT; Diz Dios P
    Mini Rev Med Chem; 2009 Sep; 9(10):1147-58. PubMed ID: 19534690
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
    Frothingham R
    Pharmacotherapy; 2001 Dec; 21(12):1468-72. PubMed ID: 11765299
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function.
    Enzweiler KA; Bosso JA; White RL
    Pharmacotherapy; 2003 Jul; 23(7):925-32. PubMed ID: 12885105
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Moxifloxacin as postoperative prophylaxis for Enterococcus faecalis-induced endophthalmitis after cataract surgery in aphakic rabbits.
    Tasaka Y; Suzuki T; Kawasaki S; Uda T; Mito T; Uno T; Ohashi Y
    J Ocul Pharmacol Ther; 2013 May; 29(4):403-9. PubMed ID: 23249386
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Fluoroquinolone resistance in bacterial isolates from ocular infections: Trend in antibiotic susceptibility patterns between 2005-2020.
    Chatterjee S; Agrawal D; Gomase SN; Parchand SM; Gangwe AB; Mishra M
    Indian J Ophthalmol; 2022 Dec; 70(12):4391-4398. PubMed ID: 36453351
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams.
    Behra-Miellet J; Dubreuil L; Jumas-Bilak E
    Int J Antimicrob Agents; 2002 Nov; 20(5):366-74. PubMed ID: 12431872
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae.
    Tasso L; de Andrade C; Dalla Costa T
    Int J Antimicrob Agents; 2011 Oct; 38(4):307-13. PubMed ID: 21802907
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Comparative research of the efficacy of the gatifloxacin and levofloxacin for bacterial conjunctivitis in human eyes].
    Gong L; Sun XH; Qiu XD; Zhang YQ; Qu J; Yuan ZL; Xiong QC
    Zhonghua Yan Ke Za Zhi; 2010 Jun; 46(6):525-31. PubMed ID: 21055198
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A comparison of moxifloxacin and levofloxacin topical prophylaxis in a fluoroquinolone-resistant Staphylococcus aureus rabbit model.
    Kowalski RP; Romanowski EG; Mah FS; Sasaki H; Fukuda M; Gordon YJ
    Jpn J Ophthalmol; 2008; 52(3):211-216. PubMed ID: 18661272
    [TBL] [Abstract][Full Text] [Related]  

  • 79. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
    Rodríguez JC; Ruiz M; López M; Royo G
    Int J Antimicrob Agents; 2002 Dec; 20(6):464-7. PubMed ID: 12458143
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin.
    Steward J; Piercy T; Lever MS; Simpson AJ; Brooks TJ
    Int J Antimicrob Agents; 2006 May; 27(5):439-43. PubMed ID: 16621457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.